Johnson & Johnson (NYSE:JNJ) Shares Bought by Cidel Asset Management Inc.

Cidel Asset Management Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 7.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 197,935 shares of the company’s stock after purchasing an additional 14,453 shares during the period. Johnson & Johnson comprises 1.3% of Cidel Asset Management Inc.’s holdings, making the stock its 25th biggest holding. Cidel Asset Management Inc.’s holdings in Johnson & Johnson were worth $32,608,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 0.7% in the 1st quarter. BlackRock Inc. now owns 189,690,998 shares of the company’s stock worth $31,175,717,000 after purchasing an additional 1,379,656 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Johnson & Johnson by 1.8% in the first quarter. Geode Capital Management LLC now owns 40,825,241 shares of the company’s stock worth $6,691,186,000 after acquiring an additional 716,136 shares in the last quarter. Morgan Stanley increased its position in shares of Johnson & Johnson by 0.8% in the first quarter. Morgan Stanley now owns 24,305,948 shares of the company’s stock worth $3,994,681,000 after acquiring an additional 194,920 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Johnson & Johnson by 0.8% in the first quarter. Nuveen Asset Management LLC now owns 14,395,550 shares of the company’s stock worth $2,365,909,000 after acquiring an additional 119,687 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Johnson & Johnson by 1.8% in the first quarter. Swiss National Bank now owns 11,038,366 shares of the company’s stock worth $1,814,155,000 after acquiring an additional 192,000 shares in the last quarter. 67.29% of the stock is currently owned by institutional investors.

Shares of JNJ stock traded up $0.86 during trading on Wednesday, hitting $165.66. 199,293 shares of the company were exchanged, compared to its average volume of 7,095,660. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.13 and a current ratio of 1.39. The firm has a market capitalization of $436.10 billion, a price-to-earnings ratio of 24.78, a P/E/G ratio of 2.23 and a beta of 0.71. The business’s 50-day simple moving average is $172.45 and its 200 day simple moving average is $167.19. Johnson & Johnson has a twelve month low of $133.65 and a twelve month high of $179.92.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.19. The firm had revenue of $23.31 billion during the quarter, compared to analysts’ expectations of $22.54 billion. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The company’s revenue was up 27.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.67 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 9.65 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th were paid a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend was Monday, August 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 52.80%.

Several research analysts have recently weighed in on JNJ shares. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price on the stock. in a research report on Tuesday, September 7th. Finally, Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $190.38.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More: Inflation

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.